Channel Therapeutics CORP Form 4 insider transactions

Pelthos Therapeutics Inc.'s CFO, Francis Knuettel II, was granted 33,472 restricted stock units and 102,000 stock options, both with an exercise price of $13.50 per share, following a 1-for-10 reverse stock split.

Pelthos Therapeutics Director Todd C. Davis received grants of restricted stock units and stock options totaling 77,338 shares at an exercise price of $13.50, following a 1-for-10 reverse stock split.

Pelthos Therapeutics Inc. Director Ezra M. Friedberg was granted 19,108 restricted stock units and 58,230 stock options, both with an exercise price of $13.50 per share, vesting quarterly over three years.

Pelthos Therapeutics Inc. Director Richard Malamut was granted 19,108 restricted stock units and 58,230 stock options, vesting quarterly over three years, following a 1-for-10 reverse stock split.

Ezra M. Friedberg, a Director and 10% Owner of Pelthos Therapeutics Inc., reported significant changes in his beneficial ownership, including the acquisition of 80,000 common shares by entities he manages, concurrent with a 1-for-10 reverse stock split.

Pelthos Therapeutics Inc.'s Chief Financial Officer, Francis Knuettel II, acquired common stock and convertible preferred stock on July 1, 2025, following a 1-for-10 reverse stock split.

Pelthos Therapeutics Inc. Director and 10% owner Todd C. Davis reported the indirect acquisition of over 4.6 million common shares through Ligand Pharmaceuticals Inc. following a 1-for-10 reverse stock split and a merger transaction.

Ligand Pharmaceuticals Inc. has significantly increased its beneficial ownership in Pelthos Therapeutics Inc. through the acquisition of common stock and convertible preferred stock following a strategic merger and a 1-for-10 reverse stock split.

Director Chia-Lin Simmons reports the grant of stock options for 25,000 shares of Channel Therapeutics Corp, vesting upon a change of control.

Francis Knuettel II, CEO of Channel Therapeutics, was granted stock options to purchase 53,988 shares of common stock on April 11, 2025.

Todd C. Davis, a director at Chromocell Therapeutics, was granted 49,605 restricted stock units on November 13, 2024, at an exercise price of $0.64 per share.

Richard Malamut, a director at Chromocell Therapeutics, was granted 24,533 restricted stock units on November 13, 2024.

Ezra Friedberg, a director at Chromocell Therapeutics, was granted 24,533 restricted stock units on November 13, 2024.

Director Richard Malamut reports purchasing 10,400 shares of Chromocell Therapeutics at an average price of $0.9447.

Francis Knuettel II, CEO of Chromocell Therapeutics, reports purchases of common stock through the Lara Knuettel Revocable Trust.

CEO Francis Knuettel II reports purchases of Chromocell Therapeutics Corp [CHRO] common stock through the Lara Knuettel Revocable Trust on September 10 and 11, 2024.

CEO Francis Knuettel II reports gifting 20,000 shares of Chromocell Therapeutics Corp stock.

Francis Knuettel II, CEO, President, CFO, Treasurer, and Secretary of Chromocell Therapeutics, files an amended Form 4 to correct a previous report regarding stock options acquired by Camden Capital LLC.

Director Chia-Lin Simmons reports acquisition of stock options in Chromocell Therapeutics.

Eric Lang, Chief Medical Officer of Chromocell Therapeutics Corp, reports the acquisition of stock options for 130,000 shares of common stock.

Director Ezra Friedberg reports acquisition of 64,498 restricted stock units in Chromocell Therapeutics.

Director Richard Malamut reports acquisition of restricted stock units in Chromocell Therapeutics.

Francis Knuettel II, CEO, President, CFO, Treasurer, and Secretary of Chromocell Therapeutics Corp, was granted stock options to purchase shares of common stock.

Todd C Davis, a director of Chromocell Therapeutics Corp, acquired 128,977 restricted stock units at an exercise price of $1.30 per share on June 14, 2024.

Ezra Friedberg, a director at Chromocell Therapeutics, amends a previous SEC Form 4 filing to include the purchase of 16,667 shares during the company's initial public offering (IPO).